iX Biopharma's Sublingual NAD+ Wafers Show Promising Results in Human Trial

MT Newswires07-10

iX Biopharma (SGX:42C) disclosed preliminary findings from a pilot study conducted by NAD Laboratory in London, according to a Tuesday filing on the Singapore Exchange.

The study evaluated the impact of iX Biopharma's sublingual NAD+ wafers (SL-NAD+) on NAD+ levels in nine healthy individuals.

According to the study, SL-NAD+ wafers increased blood NAD+ levels by an average of 59% at two weeks and 76% at six weeks compared to baseline measurements.

Participants also reported improvements in energy levels, mood, sleep quality, mental clarity, and physical strength throughout the study period, with no significant adverse effects noted.

NAD+ levels naturally decline with age and are associated with various age-related health concerns. SL-NAD+ offers a non-invasive method to potentially support cellular health and overall well-being.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2450802880?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-10 10:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2450802880","market":"sg","top_or_hot":-1,"title":"iX Biopharma's Sublingual NAD+ Wafers Show Promising Results in Human Trial","media":"MT Newswires","content":"<html><body><p> iX Biopharma (SGX:42C) disclosed preliminary findings from a pilot study conducted by NAD Laboratory in London, according to a Tuesday filing on the Singapore Exchange.</p><p>The study evaluated the impact of iX Biopharma's sublingual NAD+ wafers (SL-NAD+) on NAD+ levels in nine healthy individuals.</p><p>According to the study, SL-NAD+ wafers increased blood NAD+ levels by an average of 59% at two weeks and 76% at six weeks compared to baseline measurements.</p><p>Participants also reported improvements in energy levels, mood, sleep quality, mental clarity, and physical strength throughout the study period, with no significant adverse effects noted.</p><p>NAD+ levels naturally decline with age and are associated with various age-related health concerns. SL-NAD+ offers a non-invasive method to potentially support cellular health and overall well-being.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>iX Biopharma's Sublingual NAD+ Wafers Show Promising Results in Human Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\niX Biopharma's Sublingual NAD+ Wafers Show Promising Results in Human Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-10 10:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>iX Biopharma (SGX:42C) disclosed preliminary findings from a pilot study conducted by NAD Laboratory in London, according to a Tuesday filing on the Singapore Exchange.The study evaluated the impact ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"42C.SI","symbol_name":"IX生物制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2450802880","we_media_id":"1060499803","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2450802880","pubTimestamp":1720579222,"sourceInfo":null,"weMediaInfo":{"media_name":"MT Newswires","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1060499803","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"iX Biopharma (SGX:42C) disclosed preliminary findings from a pilot study conducted by NAD Laboratory in London, according to a Tuesday filing on the Singapore Exchange.The study evaluated the impact o","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"42C.SI":"IX生物制药","BK6506":"制药与医学研究概念","BK6079":"制药"},"translate_title":"iX Biopharma的舌下NAD+晶片在人体试验中显示出有希望的结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"42C.SI":0.9},"content_text":"iX Biopharma (SGX:42C) disclosed preliminary findings from a pilot study conducted by NAD Laboratory in London, according to a Tuesday filing on the Singapore Exchange.The study evaluated the impact of iX Biopharma's sublingual NAD+ wafers (SL-NAD+) on NAD+ levels in nine healthy individuals.According to the study, SL-NAD+ wafers increased blood NAD+ levels by an average of 59% at two weeks and 76% at six weeks compared to baseline measurements.Participants also reported improvements in energy levels, mood, sleep quality, mental clarity, and physical strength throughout the study period, with no significant adverse effects noted.NAD+ levels naturally decline with age and are associated with various age-related health concerns. SL-NAD+ offers a non-invasive method to potentially support cellular health and overall well-being.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2450802880"}